Q32 Bio Inc. (Nasdaq: QTTB), a US-based clinical stage biotechnology company, announced on Monday that it is joining the Russell 3000 Index at the conclusion of the 2024 Russell Indexes annual reconstitution, effective upon the US market opening effective 1 July 2024.

Investment managers and institutional investors use Russell indexes for index funds and as benchmarks for active investment strategies. Lee Kalowski, Q32 Bio president and chief financial officer, said, 'We are pleased to be included in the Russell 3000 Index as we approach our anticipated milestones, progress our pipeline for severe autoimmune and inflammatory diseases, and continue to expand our shareholder base.'